OnKure Therapeutics, Inc. OKUR Business Segments — Allocated Share Based Compensation Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by OnKure Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about OnKure Therapeutics, Inc.'s business segments — allocated share based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OnKure Therapeutics, Inc.'s business segments — allocated share based compensation expense?
- OnKure Therapeutics, Inc. (OKUR) reported business segments — allocated share based compensation expense of $2.78M in Q1 2026.
- How has OnKure Therapeutics, Inc.'s business segments — allocated share based compensation expense changed year-over-year?
- OnKure Therapeutics, Inc.'s business segments — allocated share based compensation expense increased by 1.3% year-over-year, from $2.75M to $2.78M.
- What does business segments — allocated share based compensation expense mean?
- Represents the non-cash expense recognized for equity-based awards granted to employees and consultants working within the clinical research segment. This metric reflects the cost of talent retention and alignment through stock-based incentives. Investors use this to understand the dilution impact and the true economic cost of the research workforce.